All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @angeladh914 on TikTok · 533s|Watch on TikTok

Ozempic journey videos: what week 23 results actually mean

AngelD💜 ❌

TikTok creator

2.6K viewsWatch on TikTok

Quick answer

Semaglutide (Ozempic at 0.5-1mg weekly for type 2 diabetes, Wegovy at up to 2.4mg weekly for chronic weight management) is FDA-approved and supported by large randomized controlled trials showing 10-15% body weight reduction over 68 weeks. A1C reductions of 1.0-1.4 percentage points have been demonstrated in diabetic populations. Long-term use is generally required to maintain outcomes, as weight regain after discontinuation is well-documented in the literature.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Ozempic journey videos: what week 23 results actually mean, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Ozempic journey videos: what week 23 results actually mean" from AngelD💜 ❌. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide (Ozempic at 0.

The reason this review is not generic is the source wording and the canonical claim label "glp1 my ozempic journey week 23 a journey to better health myozem." In this clip, the useful excerpt is: "My Ozempic Journey Week 23!" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

A1C reductions of approximately 1.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide (Ozempic at 0.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide (Ozempic at 0.5-1mg weekly for type 2 diabetes, Wegovy at up to 2.4mg weekly for chronic weight management) is FDA-approved and supported by large randomized controlled trials showing 10-15% body weight reduction over 68 weeks. A1C reductions of 1.0-1.4 percentage points have been demonstrated in diabetic populations. Long-term use is generally required to maintain outcomes, as weight regain after discontinuation is well-documented in the literature.
  • STEP 1 trial data shows average weight loss of 14.9% over 68 weeks on 2.4mg semaglutide weekly, meaning week 23 results are mid-trajectory, not final outcomes.
  • A1C reductions of approximately 1.0-1.4 percentage points were demonstrated in the SUSTAIN-6 trial for diabetic patients, but only under supervised clinical conditions with appropriate dosing.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • STEP 1 trial data shows average weight loss of 14.9% over 68 weeks on 2.4mg semaglutide weekly, meaning week 23 results are mid-trajectory, not final outcomes.
  • A1C reductions of approximately 1.0-1.4 percentage points were demonstrated in the SUSTAIN-6 trial for diabetic patients, but only under supervised clinical conditions with appropriate dosing.
  • STEP 4 (Rubino et al., 2021, JAMA) found two-thirds of lost weight returns within one year of stopping semaglutide, a fact almost never discussed in progress update videos.
  • Compounded semaglutide is not FDA-approved and is not considered equivalent to brand-name Ozempic or Wegovy in formulation or quality assurance.
  • Dietary changes made while on GLP-1 therapy contribute independently to outcomes. The drug alone is not the whole story, per Davies et al., 2021.
  • Nausea affects more than 40% of semaglutide users in early titration phases. Week 23 content rarely reflects the full side effect profile.
  • Ozempic is FDA-approved at 0.5-1mg weekly for type 2 diabetes. Wegovy at 2.4mg weekly is the weight management indication. These are different products with different approved uses.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What's this video probably claiming?

Week 23 of an Ozempic journey video almost certainly features a progress update, likely showing weight loss results, before-and-after style content, and commentary on how semaglutide has changed eating habits. The hashtags tell a story: #DiabeticA1CManagement suggests the creator may be framing this as diabetes management, not purely aesthetic weight loss, while #OzempicMealPlans and #HealthyMealOptions point to dietary advice being woven into the content. #SlimmerThickMe signals body composition talk. At week 23, creators in this genre typically report significant total weight loss, reduced appetite, and lifestyle changes they attribute to the drug. They often mix genuine medical experience with optimization tips, meal suggestions, and enthusiasm that can blur the line between personal testimony and medical guidance. That blurring is exactly what needs scrutiny.

What does the science actually show?

The SUSTAIN and STEP trial series give us actual numbers. In STEP 1 (Wilding et al., 2021, New England Journal of Medicine), participants on 2.4mg semaglutide weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% on placebo. At roughly 23 weeks, most participants are somewhere in the middle of that trajectory, often having lost 8-10% of baseline weight depending on adherence and dose titration. For A1C management specifically, the SUSTAIN-6 trial (Marso et al., 2016, NEJM) showed semaglutide 0.5mg and 1.0mg reduced A1C by approximately 1.0-1.4 percentage points. What the trials also show, and creators rarely discuss at week 23, is that results are highly individual. Gastric emptying effects, nausea rates exceeding 40% in early phases, and the critical role of caloric deficit all shape outcomes in ways a single person's journey cannot represent.

Where does the social media noise diverge from clinical reality?

The biggest gap is attribution. When someone on semaglutide changes their diet, increases activity, and loses weight, the drug gets 100% of the credit in the caption. Research is more nuanced. Davies et al. (2021, Lancet) showed that behavioral counseling combined with GLP-1 agonists produces meaningfully better outcomes than the drug alone, yet meal plan content on TikTok rarely acknowledges that the food changes are doing real work. The second gap is sustainability framing. Videos at week 23 are inherently cherry-picked moments, often near peak momentum. The STEP 4 trial (Rubino et al., 2021, JAMA) found that participants who discontinued semaglutide regained two-thirds of lost weight within one year. That is almost never in the caption. Third, the A1C hashtag raises a concern: framing Ozempic use primarily as a diabetes management tool while posting weight loss aesthetics can confuse viewers about indication, dosing differences between Ozempic and Wegovy, and the distinction between off-label and on-label prescribing.

What should you actually know?

Semaglutide works through GLP-1 receptor agonism, reducing appetite signaling, slowing gastric emptying, and improving insulin sensitivity. It is a legitimate medication with strong trial evidence. But a week 23 TikTok update is not a clinical outcome. Individual variability is substantial, and factors including baseline BMI, comorbidities, dose achieved, and dietary quality all affect results. If you are considering semaglutide for weight management or type 2 diabetes, the conversation belongs with a licensed provider who can review your metabolic panel, A1C if relevant, cardiovascular risk factors, and contraindications including personal or family history of medullary thyroid carcinoma. Compounded semaglutide products, which many patients access off-label, are not equivalent to FDA-approved Ozempic or Wegovy formulations. The FDA has flagged this distinction explicitly. Meal plans shared in these videos may be reasonable, but they are not personalized medical nutrition therapy. A registered dietitian who understands GLP-1 pharmacology is a different resource than a week 23 TikToker.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

AngelD💜 ❌ · TikTok creator

2.6K views on this video

My Ozempic Journey Week 23!!! A journey to better health!!!! #myozempicjourneyweek23 #DiabeticA1CManagement #HealthyMealOptions #OzempicMealPlans #healthylifestyle #HealthyEating #SlimmerThickMe #LetsGoViral #FYP

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial data shows average weight loss of 14.9%?

STEP 1 trial data shows average weight loss of 14.9% over 68 weeks on 2.4mg semaglutide weekly, meaning week 23 results are mid-trajectory, not final outcomes.

What does the video say about a1c reductions of approximately 1.0-1.4 percentage points were demonstrated in?

A1C reductions of approximately 1.0-1.4 percentage points were demonstrated in the SUSTAIN-6 trial for diabetic patients, but only under supervised clinical conditions with appropriate dosing.

What does the video say about step 4 (rubino et al., 2021, jama) found two-thirds of?

STEP 4 (Rubino et al., 2021, JAMA) found two-thirds of lost weight returns within one year of stopping semaglutide, a fact almost never discussed in progress update videos.

What does the video say about compounded semaglutide?

Compounded semaglutide is not FDA-approved and is not considered equivalent to brand-name Ozempic or Wegovy in formulation or quality assurance.

What does the video say about dietary changes made while on glp-1 therapy contribute independently to?

Dietary changes made while on GLP-1 therapy contribute independently to outcomes. The drug alone is not the whole story, per Davies et al., 2021.

What does the video say about nausea affects more than 40% of semaglutide users in early?

Nausea affects more than 40% of semaglutide users in early titration phases. Week 23 content rarely reflects the full side effect profile.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by AngelD💜 ❌, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.